Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

Rentschler Biopharma SE announced a strategic realignment, exiting the cell and gene therapy sector and closing its Stevenage, UK site1 3.

The decision is due to slower-than-expected growth in the cell and gene therapy market, with demand not meeting expectations1 3.

The company will focus on biologics manufacturing, leveraging recent investments in Laupheim, Germany, and Milford, MA, USA1 3.

Rentschler Biopharma's Milford, MA site is now fully operational with a new production line featuring four 2,000 L single-use bioreactors1 7.

The company made its largest-ever investment at its Laupheim headquarters in 2024 to enhance production efficiency7.

CEO Benedikt von Braunmühl emphasized the company's commitment to areas with the greatest demand and value potential3 7.

Rentschler Biopharma will continue evaluating opportunities in biologics while leveraging its expertise in biopharmaceutical manufacturing1 3.

The company has expressed gratitude to its Stevenage-based employees and committed to supporting them during the transition1 3.

This strategic shift aligns with the company's long-term growth strategy and response to evolving market conditions1 3 7.

Sources: